Thursday, April 2, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

New expectations for herd immunity timeline, both in the US and internationally

In certain places, the COVID-19-vaccine effort has hit a few speed bumps; stockpiles have accumulated, and deployment to vulnerable countries and at-risk groups has been slower than expected. Nonetheless, experts have expressed confidence that safe and highly efficacious vaccines are reaching the market, and we are beginning to see “the light at the end of the tunnel” of this devastating pandemic. The epidemiological end to the COVID-19 pandemic seemed like an optimistic dream a few short months ago, but, with the development, approval, and rollout of several vaccines, it is now practically realizable in much of the world.

To arrive at the postpandemic era, in which populations experience herd immunity, vast numbers of dedicated individuals will need to continue working intensely in the months and years ahead.

With all the many issues and delays, it is safe to assume we are less confident about reaching herd immunity in Q3 of 2021.

Source: McKinsey & Co.

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!